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Abstract
HIF-1a is overexpressed in many human cancers compared to normal tissues due to the interaction of a multiplicity of
factors and pathways that reflect specific genetic alterations and extracellular stimuli. We developed two HIF-1a chimeric
reporter systems, HIF-1a/FLuc and HIF-1a(DODDD)/FLuc, to investigate the tightly controlled level of HIF-1a protein in
normal (NIH3T3 and HEK293) and glioma (U87) cells. These reporter systems provided an opportunity to investigate the
degradation of HIF-1a in different cell lines, both in culture and in xenografts. Using immunofluorescence microscopy, we
observed different patterns of subcellular localization of HIF-1a/FLuc fusion protein between normal cells and cancer cells;
similar differences were observed for HIF-1a in non-transduced, wild-type cells. A dynamic cytoplasmic-nuclear exchange of
the fusion protein and HIF-1a was observed in NIH3T3 and HEK293 cells under different conditions (normoxia, CoCl2
treatment and hypoxia). In contrast, U87 cells showed a more persistent nuclear localization pattern that was less affected
by different growing conditions. Employing a kinetic model for protein degradation, we were able to distinguish two
components of HIF-1a/FLuc protein degradation and quantify the half-life of HIF-1a fusion proteins. The rapid clearance
component (t1/2 ,4–6 min) was abolished by the hypoxia-mimetic CoCl2, MG132 treatment and deletion of ODD domain,
and reflects the oxygen/VHL-dependent degradation pathway. The slow clearance component (t1/2 ,200 min) is consistent
with other unidentified non-oxygen/VHL-dependent degradation pathways. Overall, the continuous bioluminescence
readout of HIF-1a/FLuc stabilization in vitro and in vivo will facilitate the development and validation of therapeutics that
affect the stability and accumulation of HIF-1a.
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Introduction
The HIF-1 (hypoxia inducible transcriptional factor 1) controls
the expression of genes involved in critical aspects of cancer
biology, such as angiogenesis, glucose metabolism, cell survival,
invasion and tumor progression [1,2,3,4,5,6,7]. HIF-1 is a
heterodimeric protein complex composed of two subunits: a stable
and constitutively expressed HIF-1b, and an inducible, O2- and
growth factor-regulated HIF-1a-subunit [8,9]. HIF-1a protein is
constantly modified posttranslationally by prolyl hydroxylases at
Pro402 and/or Pro564 within the oxygen-dependent degradation
(ODD) domain which promotes binding with pVHL (von Hippel-
Lindau protein) and subsequent targeting for rapid proteasomal
degradation. The half-life of HIF-1a protein, as determined by
standard immunoblotting method, is about 5–8 min under normal
oxygenated conditions [10,11,12]. It has been proposed, that
interaction between pVHL and HIF-1a occurs in the nucleus,
where HIF-1a protein is ubiquitinated and then exported to the
cytoplasm for further proteasomal degradation [13]. Under
hypoxic conditions, the prolyl hydroxylation reaction is inhibited
and pVHL-HIF-1a interaction is abrogated, resulting in HIF-1a
accumulation in the nucleus and dimerization with HIF-1b
[14,15]. The degradation of HIF-1a is also regulated in an O2-
independent manner by the competitive binding to either heat
shock protein 90 (HSP90), which stabilizes the protein [16,17], or
to the anchoring protein (RACK1), which leads to HIF-1a
degradation by an oxygen-independent process [18].
HIF-1a is overexpressed in many human cancers compared to
normal tissues [19,20], and this overexpression is due to the
interaction of a multiplicity of factors and pathways that reflect
specific genetic alterations and extracellular stimuli (e.g., hypoxia)
that impact on both synthesis and degradation [21]. The
activation of oncogenes (H-ras and v-src) involving signaling
cascades (PI3K and MAPK), as well as loss of function mutations
in tumor suppressor genes (VHL, PTEN and p53), have also been
shown to result in HIF-1a protein accumulation and increased
expression of downstream HIF-1 target genes [9,21,22,23,24].
The objective of this study was to investigate and compare the
tightly controlled level of HIF-1a protein in normal and tumor
cells by imaging the dynamic response of different fusion variants
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accomplish this goal, we engineered several different reporter
constructs and generated reporter cell lines to study the dynamic
stability of HIF-1a under hypoxia and in the presence of a prolyl
hydroxylation inhibitor - CoCl2, a protein synthesis inhibitor -
cycloheximide, and a proteasomal degradation inhibitor - MG132.
Using immunofluorescence microscopy, we observed different
patterns of subcellular localization of HIF-1a/FLuc fusion protein
between normal cells and cancer cells; similar differences were
observed for HIF-1a in non-transduced, wild-type cells. By
employing a kinetic model for protein degradation, we were able
to quantify the half-life of HIF-1a/FLuc noninvasively in cells with
different genetic backgrounds using a more sensitive dynamic
bioluminescence imaging technique.
Materials and Methods
Generation of reporter vectors
All DNAmanipulationswereperformed usingrestrictionenzymes,
T4 DNA ligase, CIP, and buffers according to standard procedures
and manufacturer’s instructions (Life Technologies, Inc., Roche and
New England BioLabs, CA, USA). The initial retroviral vector SFG-
FLuc-IRES2-GFP was developed through several steps using SFG-
TK/GFP plasmid as a backbone [25] (Fig. 1A (1)). This vector
contained constitutively expressed FLuciferase and GFP (green
fluorescent protein) separated by an internal ribosome entry site
(IRES2) [26]. Based on this plasmid, two additional retroviral vectors
were developed: SFG-HIF-1a/FLuc-IRES2-GFP, SFG-HIF-
1a(DODDD)/Fluc-IRES2-GFP (Fig. 1A (2, 3)).
Figure 1. A. Structure of the reporter systems and development of the reporter cells. The retroviral plasmid with constitutively expressed
Firefly Luicferase and GFP (1) was used as the backbone plasmid for developing the HIF-1a reporter systems and served as a control vector for Firefly
Luciferase. Vector (2) contains a fusion between the full length cDNA of HIF-1a and Firefly Luciferase genes in a bicistronic cassette with IRES2-GFP.
Vector (3) contains the fusion gene of HIF-1a with a deleted oxygen-dependent degradation domain (ODDD) sequence and FLuciferase in a
bicistronic cassette with IRES2-GFP. B,C. Bioluminescence imaging of HIF-1a/Fluc accumulation in NIH3T3 reporter cells. Temporal
changes in bioluminescence from HIF-1a/FLuc expression (B) and HIF-1a(DODDD)/Fluc expression (C) in NIH3T3 cells after treatment with CoCl2
(100 mM). Note the log-order difference in bioluminescence intensity (ordinate scale) between panels (B) and (C). NIH3T3 cells lysates were used for
Western blotting with antibodies to HIF-1a to identify the HIF-1a/FLuc fusion protein and endogenous HIF-1a in the same cells.
doi:10.1371/journal.pone.0005077.g001
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cDNA for HIF-1a was amplified from pCEP4-HIF-1a (ATCC,
VA, USA) by 4 step PCR amplification with one primer for the 59
end of HIF-1a cDNA that incorporated a NcoI restriction site: 59-
CGTCTTCCATGGATGCGGCTGCCTTTGCGGCTGCTTC-
CTTTGCGGCTGC and four consecutive primers for elongation of
the PCR amplified fragment, and by introducing a sequence
encoding for 30 amino acid linker downstream HIF-1a [27]: 59-
ACCATCCTCTAGAATGGAGGGCGCCGGCGGCGCGA, 59-
CGGCGGCTTCTGCAAGGTTAACTTGATCCAAAGCTCTG-
AGTAATTCTTC, 59-CAGCTTCTTTCGCTGCGGCCCTCT-
TTTGCGGCGGCTTCTGCAAGGTTAAC 59-GGCTGCTTC-
CTTTGCGGCTGCTTCCTTGGCTGCAGCTTCTTTCGCT-
GCG. The resulting PCR product was used for NcoI/XbaIl i g a t i o n
into the SFG-FLuc-IRES2-GFP backbone to obtain the final plasmid
SFG-HIF-1a/FLuc-IRES2-GFPwherethefusiongeneHIF-1a/FLuc
was separated from the GFP by an IRES element.
To construct a HIF-1a/FLuc fusion gene with a deleted oxygen-
dependent degradation domain (DODDD), corresponding to
1206–1813 bp in the HIF-1a ORF and 401–603 amino acids
the HIF-1a protein, the following approach was used. PCR
primers, corresponding to the N-terminal and C–terminal ends of
the HIF-1a protein and two additional primers corresponding to
the internal part of protein without ODD domain were designed:
59-AAAAGAAAAGTCTCGAGATGCAGC, 59-ATAGTTTAG-
CGGCCGCAGCAAAGTTAA, 59-CATAGAAGCGGCCGCA-
GACTCAAATAC, 59-GGCGGATCCTTACACGGCGATCT.
PCR products with XhoI/NotI and NotI/BamHI ends were
subcloned into the SFG-HIF-1a/Fluc-IRES2-GFP between XhoI
and BamHI sites to generate the HIF-1a(DODDD)/FLuc fusion
gene without the ODDD sequence.
SFG-FLuc-IRES2-GFP, SFG-HIF-1a/FLuc-IRES2-GFP, SFG-
HIF-1a(DODDD)/Fluc-IRES2-GFP retroviral plasmids were
transfected into a GPG293 producer cell line using LipofectAMINE
2000 (Invitrogen, CA)[28] according to the manufacturer’s
protocol. The retrovirus-containing medium was collected over
four consecutive days and stored at 280uC.
Cells transduction
All cell lines were stably transduced by incubating 50%
confluent cell cultures with a virus-containing medium for
12 hours in presence of polybrene (8 mg/ml; Sigma, St.Louis,
MO, USA). Cells were sorted using the fluorescence-activated cell
sorter (FACS; BD Bioscience, CA, USA) with identical gates to
obtain populations of cells with the same GFP fluorescence level
(Fig. S1).
In vitro bioluminescence assays
Stably transduced and sorted cells were seeded in 6-well plates.
The medium was changed 24 h later with fresh medium
containing CoCl2 (100 mM) (Sigma-Aldrich, St. Louis, MO,
USA). Alternatively cells were incubated under hypoxic conditions
(2.5% O2) during 3, 6, 8 and 24 h in a HERA cell 150 chamber
(Thermo Electron Corporation, USA). The cells were collected in
PBS with 10% FCS, counted with a disposable hemocytometer
(Incyto, SKC Co., Republic of Korea), and assessed for viability by
trypan blue staining. Bioluminescence assays were always
performed on 2610
4 cells in 96-well plates using 10 mlo f
Bright-Glo Luciferase solution (Promega Cor., Madison, WI,
USA). An IVISH Imaging System 200 (Caliper Life Sciences, CA)
and Photon imager (Biospace, Paris, France) were used to measure
FLuciferase activity. The acquisition time was dependent on the
signal intensity in the different reporter cell lines. All measure-
ments are reported as photons/second/2610
4 cells, folds or % of
FLuciferase activity.
Protein degradation assay and half-life calculation
Cells were seeded into 96-well plates. After 3–4 hours of
incubation in standard conditions, the protein synthesis inhibitor
cycloheximide (100 mg/ml) (Sigma-Aldrich, St. Louis, MO, USA)
was added for the indicated periods of time to the medium. In the
experiments with CoCl2 treatment, cells were pretreated with
CoCl2 for 3 h which was either maintained in the medium during
cycloheximide exposure or was removed before exposure to
cycloheximide. Following incubation, the cells were assayed for
bioluminescence using Bright-Glo Luciferase solution. FLuciferase
activity of the test cells was normalized to that of untreated control
cells and expressed as % of control. The times profiles for
FLuciferase activity were generated and fitted to either a single or
double exponential equation to estimate the degradation rate of
FLuicferase activity (reflecting the amount of HIF-1a/FLuc fusion
protein): % of control=A0?e^(2ka?t) or A0?e^(2ka?t)+-
B0?e^(2kb?t), respectively. The half-life was calculated by: t1/2=
ln2/k. Data fitting was performed using KaleidaGraph (Synergy
Software version 3.6.4).
Western blotting
Cell lines underwent protein extraction using Mammalian
Protein Extraction Reagent (Pierce, Rockford, IL, USA) or SDS
sample buffer (62.5 mM Tris-HCl/pH 6.8, 2% w/v SDS, 10%
Glycerol, 50 mM DTT). Protein concentrations were determined
by Bio-Rad protein assay (Bio-Rad, Hercules, CA, USA). The
proteins in equivalent amounts (10–40 mg/well) were separated by
electrophoresis in a NuPAGE gradient 4–12% Bis-Tris Gel
(Invitrogen, Carlsbad, CA, USA) and were immuno-blotted with
anti-HIF-1a (RD Systems, Minneapolis, MN, USA) at a 1:200
dilution, and anti-ß-actin ( Abcam Inc., Cambridge, MA, USA ) at
a 1:5,000 dilution antibodies. Immune complexes were detected
by horseradish-peroxidase-labeled antibodies and enhanced
chemiluminescence reagent (Amersham, Buckinghamshire, UK).
Immunofluorescence microscopy
Adherent cells were fixed with 4% paraformaldehyde in PBS for
12 min, washed three times with PBS, permeabilized with 0.2%
Triton X-100 in Superblock (Pierce, Rockford, Il) for 30 min and
washed again with PBS (at room temperature). After blocking
nonspecific binding with ImageIT (Molecular Probes, Carlsbad,
CA) for 30 min at room temperature, the cells were incubated
with mouse anti-HIF-1a (BD Biosciences, San Jose, CA and RD
Systems, Minneapolis, MN, USA) at 1:50 dilution in Superblock
overnight at 4uC. Primary antibodies were detected by incubation
with a goat anti-mouse secondary antibody conjugated to Alexa-
568 (Molecular Probes Carlsbad, CA) diluted in Superblock at
1:100, at room temperature for 1 h. Following washing in PBS,
cells were mounted in Vectashield (Burlingame, CA) containing
1.5 mg/ml DAPI. Fluorescence images were acquired at 640
magnification using an Olympus BX40 fluorescence microscope
(Olympus America, Inc.) with CCD camera. DAPI, GFP and
HIF-1a were imaged using blue, green and red filters respectively.
In vivo bioluminescence imaging
The animal protocol was approved by the Memorial Sloan-
Kettering Institutional Animal Care and Use Committee. The
U87/HIF-1a/Fluc, U87/HIF-1a(DODDD)/Fluc and U87/Fluc
reporter cells (4610
6) were injected subcutaneously onto the right
shoulder of 6-weeks old male Ncr nu/nu nude mice. After 1 week
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,6–7 mm. For the FLuciferase substrate delivery into mice, the
micro-osmotic pumps (Alzet Model 1007D) (Durect Corporation,
CA, USA), loaded with D-Luciferin (50 mg/ml) (Caliper Life
Sciences, CA, USA), were surgically implanted in the dorsal back
subcutaneously. Mice were allowed to recover for 48 h and than
imaged using IVIS imaging system before and after intraperitoneal
injection of CoCl2 (60 mg/kg). Photons emitted from the tumor
region were quantified using Living Image software (Caliper Life
Sciences, CA).
Statistical analyzes
Each experiment or assay was performed at least three times in
triplicate and representative examples are shown. Data are
reported as means6SD, applying Dunnett’s ANOVA-based
multiple comparisons procedure for comparing several treatments
(CoCl2 and hypoxia) with a single control and separately for each
reporter. P,0.05 is considered significant.
Results
Development of reporter cells
Three new retroviral vectors were developed to study the
regulation of HIF-1a accumulation/degradation processes in cells.
Fusion genes containing HIF-1a ( Fig. 1A (2)) ,o ram u t a n tv a r i a n to f
the HIF-1a (DODDD) with a deleted oxygen-dependent degradation
domain (Fig. 1A (3)), were linked to the Firefly Luciferase by a
rationally designed linker of 30 amino acids [27]. GFP, separated by
anIRES2elementinthefusiongenecassettes,wasusedtoFACS-sort
GFP-positive transduced cells in order to obtain populations of cells
with similar GFP expression levels (Fig. S1). NIH3T3 (immortalized
mouse fibroblasts) and U87 (human glioblastoma) cells were stably
transduced with these reporter vectors. The reporter cell lines
included: NIH3T3/HIF1a/FLuc, U87/HIF1a/FLuc, as well as
NIH3T3/HIF-1a(DODDD)/Fluc, U87/HIF-1a(DODDD)/Fluc,
and control NIH3T3/FLuc, and U87/FLuc. We also transduced
HEK293 (human embryonic kidney) cells with the SGF-HIF1a/
FLuc-IRES2-GFP reporter system.
Bioluminescence imaging of HIF-1a levels in cells
To characterize the reporter systems, we performed several
experiments to show the functionality of the HIF1a/FLuc and
HIF-1a(DODDD)/FLuc fusion proteins in NIH3T3 reporter cells.
Bioluminescence intensity was measured following the addition of
an inhibitor of prolyl hydroxylation, a hypoxia mimetic, CoCl2
(100 mM), to the culture medium (Fig. 1B, C). An increase of
HIF-1a/FLuc expression was detectable within the first several
hours, reaching a maximum value within 3–8 h, followed by a
return toward basal levels following 24 h of treatment. These data
were confirmed by Western blotting for the fusion HIF-1a/FLuc
and for endogenous HIF-1a proteins (Fig. 1B). In the case of
reporter cells bearing the HIF-1a(DODDD)/FLuc fusion, we did
not see any significant changes in bioluminescence signal over
24 h as well as in the fusion protein (Fig. 1C).
Imaging HIF-1a levels in different cell lines
The HIF-1a/FLuc and HIF-1a(DODDD)/Fluc fusion proteins
expression in NIH3T3 fibroblasts was compared to that obtained
in reporter-transduced U87 glioma cells (Fig. 2A). The HIF1a/
FLuc basal expression under normoxia, as measured by
bioluminescence intensity, was approximately 9.5-fold higher
(p=0.006) in reporter-transduced U87 cells than in the reporter-
transduced NIH3T3 cells (Fig. 2A). Exposing the NIH3T3
reporter-transduced cells to 100 mM CoCl2 resulted in a ,15-
fold increase (p,0.0001) in bioluminescence (Fig. 2A). Moderate
hypoxia (2.5% O2) was less effective than CoCl2 in these cells, but
still resulted in a statistically significant 6-fold increase (p,0.0001)
in bioluminescence signal intensity. The U87/HIF1a/FLuc cells
demonstrated a ,10-fold (p,0.0001) and ,2-fold (p=0.0016)
increase in bioluminescence in response to CoCl2 treatment and
hypoxia, respectively (Fig. 2A). The HEK293/HIF1a/FLuc
reporter cells as well showed low normoxic baseline levels of
bioluminescence and an increase in bioluminescence following
exposure to hypoxia (2.5% O2) and CoCl2 (100 mM) (Fig. 2C).
We also measured bioluminescence of cells transduced with a
mutant-variant of HIF-1a, containing a deleted oxygen-dependent
degradation domain (DODDD) in the fusion construct (Fig. 2A).
As expected, bioluminescence activity from NIH3T3 and U87
HIF-1a(DODDD)/Fluc reporter cells under baseline normoxic
conditions was much higher than that in cells transduced with the
Figure 2. Comparison of HIF-1a/Fluc levels in NIH3T3, HEK293
and U87 cell lines. A comparison of HIF-1a/FLuc and HIF-1a(DODDD)/
Fluc bioluminescence after treatment with CoCl2 (100 mM) and under
low oxygen concentration (2.5% O2) for 6 h in NIH3T3 and U87 reporter
cells. *:p ,0.01 vs. the control. **:p ,0.0001 vs. the control (A). The
level of the expression HIF-1a/FLuc reporter and endogenous HIF-1a in
reporter cells under the same conditions (B). Bioluminescence imaging
of HEK293/HIF-1a/Fluc cells after treatment with CoCl2 (100 mM) and
under low oxygen concentration (2.5% O2) for 6 h (C).
doi:10.1371/journal.pone.0005077.g002
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NIH3T3/HIF-1a(DODDD)/Fluc reporter cells under normoxia
was ,300-fold greater (p,0.0001) than that of HIF-1a/Fluc
transduced cells. A similar comparison of U87 reporter cells
demonstrated a ,50-fold increase (p=0.0002) in bioluminescence
signal as a result of ODDD deletion. The expression levels of the
mutated HIF-1a(DODDD)/Fluc reporter in NIH3T3 and U87
cells were similar to each other and not influenced by treatment
with CoCl2 or hypoxia (Fig. 2A).
To examine whether the increase in bioluminescence was due to
HIF-1a stabilization or to an effect of CoCl2 on the FLuc reporter,
the same experiments were performed using cells constitutively
expressing Firefly Luciferase. FLuc bioluminescence intensity was
not influenced by exposure to 100 mM CoCl2 or hypoxia (2.5%
O2) (data not shown). All bioluminescence data were confirmed by
Western blotting using specific antibodies (Fig. 2B).
The analysis of HIF-1a distribution in cells by
immunofluorescence microscopy
Having characterized the behavior of the reporter proteins in the
stably transduced cell lines, we sought to investigate whether the
different genetic backgroundsofthecells influenced theintracellular
localization of HIF-1a and its fusion proteins. To show that
endogenous HIF-1a protein possess the same cytoplasmic-nuclear
trafficking patterns as the HIF-1a/FLuc reporter, we also
performed immunofluorescence staining of non-transduced, wild-
type NIH3T3, U87 and HEK293 cells. As seen by immunofluo-
rescence microscopy under normoxia HIF-1a/FLuc localization in
NIH3T3 reporter cells (Fig. 3A) and HIF-1a in wild-type NIH3T3
cells (Fig. 4A) was primarily cytoplasmic, compared to the more
equal distribution between nucleus and cytoplasm in HEK293
reporter and wild-typecells(Fig. 3C,4C). Incontrast,moreintense
nuclear staining of HIF-1a/FLuc (Fig. 3B) and wild-type HIF-1a
(Fig. 4B) was observed in U87 reporter and non-transduced cells,
respectively. Following exposure to CoCl2 there was a consistent
shift in HIF-1a/FLuc and HIF-1a localization to the nucleus in all
three cell lines. NIH3T3 reporter and wild-type cells showed
increased accumulation in both compartments, with more intense
cytoplasmic accumulation (Fig. 3A, 4A). In contrast, U87 and
HEK293 reporter-transduced and wild-type cells showed much
greater accumulation of HIF-1a/FLuc and HIF-1a in the nucleus
following CoCl2 treatment (Fig. 3B, 3C, 4B, 4C). The same
pattern of the HIF-1a/FLuc and HIF-1a re-distribution was
observed after exposure of all three reporter-transduced cell lines
to hypoxia (2.5% O2) (Fig. S2, S3, S4). Interestingly, the deletion
oftheoxygen-dependentdegradationdomainfrom HIF-1a resulted
inapredominantnuclearaccumulationofthemutantfusionprotein
under normal growth conditions, hypoxia (2.5% O2) or CoCl2
treatment, for both NIH3T3 and U87 HIF-1a(DODDD)-trans-
duced cell lines (Fig. 5 and Fig. S2, S3).
GFP fluorescence, the identifier of reporter-transduced cells,
remained unchanged under normoxia, hypoxia or CoCl2 treatment
and served as an internal control (Fig. 3, 4, 5 and Fig. S2, S3,
S4). Furthermore, the data presented in Figure 4 and Figures
S2, S3, S4 clearly demonstrate that the subcellular distribution of
the endogenous HIF-1a in wild-type cells is the same as the HIF-
1a/FLuc fusion protein in reporter-transduced cells under normal
basal growing conditions, CoCl2 treatment or hypoxia (2.5%).
Real-time imaging of HIF-1a stabilization in tumor
xenografts
To characterize the reporter systems in vivo, a series of
experiments were performed to image the stabilization of HIF-
1a following CoCl2 administration and inhibition of prolyl
hydroxylases in animals bearing a HIF-1a/FLuc reporter
xenograft. Three sets of mice bearing one of three constitutively
expressing reporter xenografts were studied: HIF-1a/FLuc, HIF-
1a(DODDD)/FLuc and FLuciferase (control). After a single
intraperitoneal injection of CoCl2 (60 mg/kg), a time-dependent
increase in tumor bioluminescence was observed in U87/HIF-1a/
FLuc xenografts. The maximum bioluminescence intensity, ,6-
fold over pretreatment values, was observed 40–90 min after
CoCl2 administration. The signal decreased gradually to basal
levels over 5 h (Fig. 6A, B). In contrast, only a slight increase in
bioluminescence after CoCl2 injection was detected in mice
bearing the U87/HIF-1a(DODDD)/FLuc or U87/Fluc control
xenografts.
Assessment of HIF-1a/FLuc and HIF-1a(DODDD)/FLuc
degradation in different cell lines
To assess pVHL-ODDD-dependent degradation of HIF-1a/
FLuc in NIH3T3 and U87 reporter cells, the time-course and the
degradation rate of the fusion proteins (HIF-1a/FLuc and HIF-
1a(DODDD)/FLuc), as well as FLuc alone was determined by
sequential bioluminescence measurements following the addition
of a protein synthesis inhibitor (cycloheximide, 100 mg/ml) to the
incubation medium (Fig. 7 and 8). Degradation of the HIF-1a/
FLuc fusion protein in reporter-transduced NIH3T3 and U87 cells
under normoxic conditions had a bi-exponential clearance, readily
separated into rapid (mean t1/2 4–6 min) and slow (mean t1/2
,200 min) kinetic phase components (Fig. 7A and 8A; Tables 1
and 2). A similar bi-exponential clearance profile of HIF-1a/
FLuc was observed in HEK293 reporter cells (Fig. 8C). In
contrast, only a single exponential, reflecting a slow clearance
phase (mean t1/2 ,160 min) was identified in both NIH3T3 and
U87 cells transduced with the HIF-1a(DODDD)/FLuc fusion
construct. Similarly, only a single, very slow clearance component
(mean t1/2 ,400 min) was identified for the constitutively
expressed, native FLuc protein under normoxic conditions in
NIH3T3/FLuc and U87/FLuc reporter cells (Fig. 7A and 8A;
Tables 1 and 2).
The presence of CoCl2 (100 mM) together with cycloheximide
(100 mg/ml) in the medium resulted in a loss of the rapid clearance
component in both NIH3T3/HIF-1a/FLuc (Fig. 7B; Table 1)
and U87/HIF-1a/FLuc cells (Fig. 8B; Table 2). The clearance
profile could be described by a single exponential with a mean
half-time of ,50 min after a 3 h or a 24 h exposure to CoCl2. The
precise mechanism for regulating the HIF-1a levels is still not
clear; both increased degradation [29] and decreased production
of the protein have been proposed [30,31]. Reappearance of the
bi-exponential clearance of the HIF-1a/FLuc fusion protein,
reflecting rapid and slow degradative phase, was again observed
after removal of CoCl2 from the incubation medium in NIH3T3
reporter-transduced cells (Fig. 7B; Table 2). The presence of
residual, non-degraded HIF-1a/FLuc protein after 90 min of
protein synthesis inhibition was demonstrated by Western blotting
(Fig. 7C), and comparable levels and rates of degradation were
observed by immunoblot for endogenous HIF-1a and HIF-1a/
FLuc. Thus, partial degradation of the fusion protein with a
persistence of a functional Firefly luciferase component is unlikely.
To demonstrate involvement of the proteasome in the degradation
of the HIF-1a, cell lines bearing the HIF-1a/FLuc reporter cells
were pretreated with a proteasome inhibitor, MG132 (10 mM for
3 h), followed by the addition of cycloheximide to the medium.
MG132 prevented HIF-1a/FLuc protein degradation in all cell
lines (Fig. 7A and 8A; Tables 1 and 2).
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components reflect different rates of cytoplasmic and nuclear
HIF-1a/FLuc protein degradation, NIH3T3/HIF-1a/FLuc re-
porter cells were analyzed by immunofluorescence microscopy
(Fig. 7D). Reporter cells were pretreated with CoCl2 for 3 h,
followed by its removal from the media and the addition of
cycloheximide for 0, 7 and 90 min. HIF-1a/FLuc distribution
within cells at 7 min after addition of cycloheximide showed slightly
more nuclear intensity and a few cells visualized by DAPI staining
and GFP expression were not visualized by anti-HIF-1a fluorescent
antibody. By 90 minutes, approximately half the reporter cells were
not visualized by anti-HIF-1a immunofluorescence (Fig. 7D),
suggesting that some cells clear the HIF-1a/FLuc fusion protein
more rapidly then other cells. GFP immunofluorescence remained
unchanged under cycloheximide treatment and was used as an
internal control to identify reporter-transduced cells (Fig. 7D).
Discussion
The two HIF-1a chimeric reporter systems that were developed
in this study provide an opportunity to investigate HIF-1a
stabilization/degradation process in different cell lines, both in
Figure 3. Immunofluorescence analysis of HIF-1a/Fluc trafficking in reporter NIH3T3, HEK293 and U87 cell lines. The NIH3T3/HIF-1a/
Fluc (A), U87/HIF-1a/Fluc (B) and HEK293/HIF-1a/Fluc (C) reporter-transduced cells were cultured under normoxic conditions or in the presence of
CoCl2 (100 mM) for 6 h. Cells were prepared for immunofluorescence as described in Materials and Methods and were incubated with the anti-HIF-1a
antibody followed by an Alexa-568-conjugated secondary antibody. Cells were also visualized for GFP expression. Fluorescence images were acquired
using the same acquisition parameters at640 magnification. All panels represent the magnified images after contrast and brightness adjustment to
visualize the subcellular localization of the protein.
doi:10.1371/journal.pone.0005077.g003
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employed the fusion between the HIF-1a-ODD domain and
Firefly Luciferase. The resulting fusion protein (ODD-Luc) is
responsive to hypoxia and hypoxia mimetics in live cells and can
be used for imaging HIF-1 oxygen/VHL-regulated activity in real-
time under different conditions [32,33,34]. A mouse that
ubiquitously expresses the ODD-Luc reporter has been success-
fully used to study the action of small molecule inhibitors of HIF
prolyl hydroxylase activity [35]. However, the ODD-Luc reporter
is useful only for studying the O2-ODD-VHL-dependent mech-
anism of regulating HIF-1a expression. HIF-1a protein levels are
also regulated by oxygen-independent mechanisms that reflect
genetic alterations in signaling pathways or regulatory factors, and
result in constitutive high levels of HIF-1a and HIF-1 transcrip-
tional activity [36,37]. Two PAS domains, A and B, of the HIF-1a
subunit in the N-terminal region frequently mediate protein-
protein interactions. One or both of the HIF-1a PAS domains
have been functionally implicated in heterodimer formation,
nuclear translocation and HIF-1a stabilization via HSP90
association [38]. The C-terminal part of the HIF-1 a is involved
Figure 4. Immunofluorescence analysis of endogenous HIF-1a trafficking in wild-type NIH3T3, HEK293 and U87 cell lines. The non-
transduced wild-type NIH3T3 (A), U87 (B) and HEK293 (C) cells were cultured under normoxic conditions or in the presence of CoCl2 (100 mM) for 6 h.
Cells were prepared for immunofluorescence as described in Materials and Methods and were incubated with the anti-HIF-1a antibody followed by
an Alexa-568-conjugated secondary antibody. Cells were also visualized for GFP expression. Fluorescence images were acquired using the same
acquisition parameters at 640 magnification. All panels represent the magnified images after contrast and brightness adjustment to visualize the
subcellular localization of the protein.
doi:10.1371/journal.pone.0005077.g004
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length of HIF-1a in reporter protein is essential for understanding
HIF-1a biology and regulation of HIF-1a stability, since this
occurs at multiple levels and involves more than the ODD
domain.
A comparison between HIF-1a/Fluc and HIF-1a(DODDD)/
Fluc expression levels, as measured by BLI, demonstrated
important differences between non-tumorigenic NIH3T3 and
HEK293 reporter cells and tumorigenic PTEN-defective U87
reporter cells. Non-tumorigenic NIH3T3 and HEK293 cells had
low basal normoxic levels of the HIF-1a/FLuc expression that
were readily detectable by BLI, but not by immunoblotting. The
higher sensitivity of the bioluminescence reporter in comparison to
the immunoblot readout in living cells provides the ability to detect
low basal levels of HIF-1a expression without exposing cells to
hypoxia or hypoxia-mimetics agents. In contrast, U87 reporter
cells had high basal levels of HIF-1a/FLuc expression. Similar
results have been shown for other cancer cells lines using an
immunoblotting assessment of endogenous HIF-1a. For example,
HIF-1a overexpression under standard growth conditions was
detected by immunoblot in metastatic breast cancer MDA-MB-
231 cells and DU145 prostate cancer cell lines [39]. Interestingly,
other cells (including MCF-7, HT-29 colon, MiaPaCa pancreatic,
A549 lung, and BX-PC3 prostate cancer cells) do not show
measurable HIF-1a levels under normoxia [39]. In addition, our
reporter systems demonstrated that various cell lines responded
differently to inhibition of a prolyl hydroxylases, either by hypoxia
or CoCl2. The reporter-transduced U87 cells showed a weaker
response to CoCl2 and hypoxia, relative to normoxic baseline
values, when compared to that observed in NIH3T3 reporter-
transduced cells.
Further validation of the reporter systems was obtained with
NIH3T3 and U87 cells bearing a mutated HIF-1a(DODDD)/Fluc
fusion gene. Both cell lines demonstrated similar high levels of
Figure 5. Immunofluorescence analysis of HIF-1a(DODDD)/Fluc trafficking in NIH3T3 and U87 reporter cell lines. NIH3T3/HIF-
1a(DODDD)/Fluc and U87/HIF-1a(DODDD)/Fluc reporter-transduced cells were cultured under normoxic conditions or in the presence of CoCl2
(100 mM) for 6 h. Cells were prepared for immunofluorescence and analyzed as described in the legend to Figure 3.
doi:10.1371/journal.pone.0005077.g005
Figure 6. Bioluminescence imaging of HIF-1a/FLuc stabilization
in vivo. Bioluminescence imaging of HIF-1a/FLuc stabilization in U87/
HIF-1a/FLuc xenograft-bearing animals was performed at the indicated
time points before and after intraperitoneal injection of CoCl2 (60 mg/
kg). D-luciferin was delivered by an implanted micro-osmotic pump (A).
Graph represents temporal changes in bioluminescence of U87/HIF-1a/
Fluc (solid circle), U87/HIF-1a(DODDD)/Fluc (grey square), U87/FLuc-
IRES-GFP (solid triangle) xenografts treated with CoCl2.D a t ai s
normalized to the baseline (pre-CoCl2) value (B).
doi:10.1371/journal.pone.0005077.g006
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ODDD deletion on the stability of the fusion protein [35]. In
addition, we demonstrated a significant BLI response in vivo when
animals bearing U87/HIF-1a/FLuc xenografts were given an i.p
injection of CoCl2, but not in animals bearing U87/HIF-
1a(DODDD)/FLuc or native FLuc expressing (control) xenografts.
The immunofluorescence analysis of the HIF-1a/FLuc subcel-
lular localization and trafficking in reporter-transduced cell lines
compared well with that of endogenous HIF-1a in wild-type cells.
However, significant differences were observed between NIH3T3,
HEK293 and U87 cells. These observations suggest a difference in
cytoplasm-nuclear trafficking of the HIF-1a and its protein fusion
between normal and tumor cells. It was previously shown under
normal oxygen tension that pVHL is engaged in a constitutive
shuttling between the nucleus and cytoplasm [13,40]. Further-
more, it is generally accepted that subcellular localization of the
HIF-a subunit in mammalian cells depends on the tumor
suppressor factor pVHL, which mediates ubiquitination of HIF-
1a. However, it has not been fully established whether
proteasomal degradation of HIF-1a occurs in the nucleus, in the
cytoplasm, or if it can take place in both compartments. Prior
reports are somewhat contradictory. According to some reports
[41,42] and the results of our immunofluorescence microscopic
studies, the HIF-1a (and HIF-1a/FLuc) translocation to the
nucleus appears to be constitutive and independent of oxygen
tension, pVHL status and the presence of a functional ODD
domain in HIF-1a [13,14]. In many cell lines HIF-1a-pVHL
interaction is abrogated in response to hypoxia or hypoxia-
mimetic agents, and HIF-1a accumulates in the nucleus
[43,44,45]. This was clearly demonstrated for the HIF-1a/FLuc
fusion in U87 and HEK293 reporter cells, and for endogenous
HIF-1a in U87 and HEK293 wild-type cells, and may be
occurring to a lesser degree in NIH3T3 cells as well. The presence
of HIF-1a/FLuc and HIF-1a in the cytoplasm and nucleus of
NIH3T3 reporter and wild-type cells exposed to CoCl2 and
hypoxia indicates continuous shuttling of the protein between the
nucleus and the cytoplasm. We speculate that the degradation of
HIF-1a in this cell type can take place in both compartments at
different rates, possibly due to a residual hydroxylation of HIF-1a
or to other non-oxygen-dependent process.
Figure 7. Assessment of HIF-1a/FLuc degradation in NIH3T3 cells under different conditions. The degradation rate of the reporter
proteins (HIF-1a/FLuc, HIF-1a(DODDD)/FLuc and FLuc) was determined by sequential bioluminescence measurements following addition of a protein
synthesis inhibitor (CHX 100 mg/ml) to the medium. The data were fitted to either a single or double exponential equation to estimate the protein
degradation rate (half-life). The graphic plots and fitted curves are representative experiments (A and B); NIH3T3 cells lysates were used for
immunoblotting with antibodies to HIF-1a to assess HIF-1a/FLuc fusion protein and endogenous HIF-1a protein degradation after CoCl2 - containing
media was removed and replaced with CHX containing media for 0, 7 and 90 min (C). Under the same conditions as that described for panel (C), the
cells were analyzed by fluorescence imaging using the same procedure, described in the legend to Figure 3.
doi:10.1371/journal.pone.0005077.g007
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HIF-1a in U87 cells under normoxic conditions indicates that
these proteins are either imported or sequestered to the nucleus in
U87 reporter cells to a greater extent than that in NIH3T3 cells,
or that their nucleus-to-cytoplasm shuttling of HIF-1a is reduced
in U87 compared to NIH3T3 cells. This is consistent with the 8–
Figure 8. Assessment of HIF-1a/FLuc degradation in U87 and HEK293 cells under different conditions. The degradation rate of the
reporter proteins (HIF-1a/FLuc, HIF-1a(DODDD)/FLuc and FLuc) was determined by sequential bioluminescence measurements following addition of
a protein synthesis inhibitor (CHX,100 mg/ml) to the medium. The data were fitted to either a single or double exponential equation to estimate the
protein degradation rate (half-life). The graphic plots show a representative set of experiments (A, B and C).
doi:10.1371/journal.pone.0005077.g008
Table 1. Determination of HIF-1a/FLuc half-life in NIH3T3 cells.
REPORTER SYSTEM CONDITIONS
T1/2 RAPID PHASE
(MINUTES)
T1/2 SLOW PHASE
(MINUTES) R MEAN N
HIF-1a/FLuc baseline 661.1 217653 0.99 4
HIF-1a/FLuc *CoCl2 (3h)RCHX 8626 5 610 0.98 4
HIF-1a/FLuc CoCl2 (3h)+CHX NF 63629 0.99 4
HIF-1a/FLuc CoCl2 (24h)+CHX NF 42613 0.98 3
HIF-1a(DODDD)/FLuc baseline NF 168680 0.94 6
HIF-1a/FLuc MG132+CHX NF 7426300 0.46 3
FLuc baseline NF 3586113 0.84 4
The mean HIF-1a/FLuc, HIF-1a(DODDD)/FLuc and FLuc protein half-lives were calculated based on 3–6 independent experiments.
*CoCl2 was removed from medium before CHX addition; NF- not found.
doi:10.1371/journal.pone.0005077.t001
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cell lines under normoxic conditions. Reduced pVHL trafficking
was recently demonstrated in clear cell renal cell carcinoma, and
was associated with strong nuclear localization of HIF-1a and
shorter patient survival [46]. Although the mechanism of HIF-1a
shuttling between nucleus and cytoplasm is poorly understood, it is
becoming evident, that HIF-1a subcellular distribution and
compartmentalization of HIF-1a degradation are regulated in a
cell-specific manner [47] and that there are significant differences
between normal cells and cancer cells. This may reflect pVHL
malfunction in cancer cells or activation of the other transduction
pathways in cancer cells.
For example, activation of the PI3K-AKT/mTOR pathway
impacts on HIF-1 through an increase in HIF-1a protein levels
[37], caused by augmentation of the protein translation [9],[48] or
by stabilization of the protein [36]. In addition, it was reported
that activation of the PI3K-AKT/mTOR pathway also causes a
major increase in nuclear localization of HIF-a/Sima from
Drosophila melanogaster, which is a functional homologue of
mammalian HIF-1a [49]. U87 human glioma cells are PTEN-
negative with increased PI3K-AKT/mTOR pathway activity
[24,50]. The difference in nuclear localization of HIF-a/Fluc and
wild-type HIF-a in this cell line compare with a normal cells is a
new observation and requires further investigation.
Deletion of the ODDD in the HIF-1a/Fluc fusion protein
prevents hydroxylation by prolyl-hydroxylases and abrogates HIF-
1a(ODDD)–pVHL interaction. The HIF-1a(ODDD)/Fluc fusion
was shown to have markedly reduced nucleus-to-cytoplasm
shuttling in NIH3T3 and U87 reporter cells, and increased
accumulation of the mutant fusion protein in the nucleus. This led
to the generation of high bioluminescence signals from the
stabilized protein in the HIF-1a(ODDD)/Fluc reporter cell lines.
These results suggest that nuclear export plays a major role in the
control of HIF-1a level in cells, adding a new level of complexity
to the regulation of this transcriptional factor.
Our immunofluorescence observations prompted us to study the
dynamics of HIF-1a/FLuc protein degradation in greater detail.
The question being addressed is whether the difference in the level
of HIF-1a/FLuc expression under baseline normoxic conditions, as
well as the ability of this fusion protein to accumulate following
exposure to CoCl2 and to moderate hypoxia, is due to a difference
in the pVHL-ODDD-dependent degradation process of HIF-1a/
FLuc indifferentcelllines.A bi-exponentialbioluminescenceprofile
of HIF-1a/FLuc protein degradation was observed in NIH3T3,
HEK293 and U87 reporter cells, indicating that both ‘‘rapid’’ and
‘‘slow’’ clearance mechanisms were operative. The half-time of the
rapid clearance in these cells was ,3–6 min and consistent with the
currently accepted half-life of HIF-1a (,5 min) under normal non-
hypoxic conditions [51,52,53]. Since the rapid phase HIF-1a/FLuc
degradation was abolished by CoCl2 treatment and by deletion of
the oxygen-dependent degradation domain from HIF-1a in
NIH3T3 and U87 reporter cells, it is likely that the rapid clearance
component reflects the dynamics of the oxygen-dependent pathway
of HIF-1a degradation in these cells. A second, slow clearance
component of the HIF-1a/FLuc degradation under normoxic
conditions in these cell lines was also revealed in our kinetic analysis
of the bioluminescence clearance profile. This component does not
reflect degradation of native FLuc protein since immunoblots of
cells taken 7, 30 and 90 min after addition of cycloheximide in the
clearance studies showed the presence of both non-degraded HIF-
1a/FLuc and non-degraded HIF-1a bands.
The dynamic profile and kinetic analysis of the HIF-1a/FLuc
degradation in NIH3T3, HEK293 and U87 cells suggests that the
rapid and slow components of degradation are compartmental-
ized. To determine, whether the observed kinetic and anatomic
compartmentalization in the cell are related, we imaged the
changes in subcellular distribution during cycloheximide-induced
clearance of the HIF-1a/FLuc protein in NIH3T3 reporter-
transduced cells by immunofluorescence imaging. Some of
reporter cells cleared their fluorescence (both cytoplasmic and
nuclear) more quickly than others. This observation suggests that
the observed kinetic compartmentalization may reflect a hetero-
geneity and difference in HIF-1a/FLuc protein degradation rate
within two or more functionally different populations of NIH3T3/
HIF-1a/FLuc cells. Despite a similar bi-phasic degradation profile
of HIF-1a/FLuc in NIH3T3 and U87 reporter cells, the basal
expression level and subcellular localization of the fusion protein in
these cell lines is very different. This suggests the involvement of
other regulatory mechanisms, which may account for differences
in the spacial distribution and stabilization of HIF-1a in cells with
different genetic backgrounds.
The expression of HIF-1a protein is modulated through different
pathways that alter HIF-1-dependent transcriptional activity and
makes the HIF-1 transcription factor an attractive target for new
drug development [4,54,55]. Several examples of HIF-1 inhibitors
that target pathways associated with HIF-1 activation have been
described [55]. For example, a number of anticancer drugs have
been shown to inhibit HIF-1, but none of these drugs target HIF-1
directly and specifically [4,54,56,57,58,59,60,61,62,63],[64,65],
[66], [63]. Some of these inhibitors are associated with signaling
pathways that include mTOR [36,67], AKT [68], Her2/Neu [9].
However, most inhibitors affect multiple signaling pathways and
only indirectly target the HIF-1 transcription factor. Therefore, the
ability to identify, visualize and validate changes in the dynamics
and stability of the HIF-1a protein is likely to be useful as a
pharmacodynamic end point and read-out of inhibition in the
development of new anticancer drugs that target HIF-1a in the
future.
Table 2. Determination of HIF-1a/FLuc half-life in U87 cells.
REPORTER SYSTEM CONDITIONS
T1/2 RAPID PHASE
(MINUTES)
T1/2 SLOW PHASE
(MINUTES) R MEAN N
HIF-1a/FLuc baseline 3.560.8 2766141 0.93 4
HIF-1a/FLuc CoCl2 (3h)+CHX NF 51616 0.97 3
HIF-1a(DODDD)/FLuc baseline NF 148648 0.91 3
HIF-1a/FLuc MG132+CHX NF 302630 0.83 3
FLuc baseline NF 4146105 0.90 4
The mean HIF-1a/FLuc, HIF-1a(DODDD)/FLuc and FLuc protein half-lives was calculated based on 3–6 independent experiments.
doi:10.1371/journal.pone.0005077.t002
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PLoS ONE | www.plosone.org 11 April 2009 | Volume 4 | Issue 4 | e5077In summary, the introduction of a HIF-1a/FLuc fusion gene into
different cell lines allowed us: 1) to study the time-dependent
accumulation and degradation of the fusion protein with greater
sensitivity and to better quantify the rate of degradation using BLI,
compared to that obtained in previous studies based on
immunoblot assays; 2) to better assess the differences in subcellular
localization and clearance of the fusion protein in normal and
tumor cells using immunofluorescence imaging, providing spatial
information to better understand HIF-1a trafficking and regula-
tion in different cells; 3) to image HIF-1a/FLuc fusion protein
stabilization and accumulation over time in animals bearing
reporter-transduced xenografts. Finally, the possibility to visualize
the modulation of HIF-1a using the chimeric reporter systems
developed in the current study, in combination with transcrip-
tional reporters based on the binding of an active HIF-1 complex
to hypoxia-response elements (HRE) which drive reporter genes
[28,69,70,71,72,73], provides the opportunity to utilize them as
tools for high-throughput screening of compounds affecting HIF-1
activity, both in vitro and in vivo.
Supporting Information
Figure S1 FACS analysis of reporter-transduced cells. GFP
expression in developed reporter cell lines was used for FACS
sorting and transduction normalization.
Found at: doi:10.1371/journal.pone.0005077.s001 (0.91 MB TIF)
Figure S2 Immunofluorescence analysis of HIF-1a and its
fusions expression in NIH3T3 cells. The NIH3T3/HIF-1a/Fluc,
NIH3T3/HIF-1a(DODDD)/Fluc and NIH3T3 non-tansduced
cells were cultured under normoxia and hypoxia for 6 h. Cells
were prepared for immunofluorescence as described in Materials
and Methods and then were incubated with the anti-HIF-1a
antibody followed by a Alexa-568-conjugated secondary antibody.
Cells were also visualized for GFP expression. Fluorescence images
were acquired at 640 magnification. All panels represent the
magnified images after adjusted contrast and brightness to
visualize the subcellular protein localization.
Found at: doi:10.1371/journal.pone.0005077.s002 (4.01 MB TIF)
Figure S3 Immunofluorescence analysis of HIF-1a and its
fusions expression in U87 cells. The U87/HIF-1a/Fluc, U87/
HIF-1a(DODDD)/Fluc and U87 non-tansduced cells were
cultured under normoxia and hypoxia for 6 h. Cells were
prepared for immunofluorescence as described in Materials and
Methods and then were incubated with the anti-HIF-1a antibody
followed by a Alexa-568-conjugated secondary antibody. Cells
were also visualized for GFP expression. Fluorescence images were
acquired at640 magnification. All panels represent the magnified
images after adjusted contrast and brightness to visualize the
subcellular protein localization.
Found at: doi:10.1371/journal.pone.0005077.s003 (3.46 MB TIF)
Figure S4 Immunofluorescence analysis of HIF-1a and HIF-
1a/FLuc expression in HEK293 cells. The reporter-transuced
HEK293/HIF-1a/Fluc and non-transduced HEK 293 cells were
cultured under normoxia or hypoxia for 6 h. Cells were prepared
for immunofluorescence as described in Materials and Methods
and then were incubated with the anti-HIF-1a antibody followed
by a Alexa-568-conjugated secondary antibody. The reporter cells
were also visualized for GFP expression. Fluorescence images were
acquired at640 magnification. All panels represent the magnified
images after adjusted contrast and brightness to visualize the
subcellular protein localization.
Found at: doi:10.1371/journal.pone.0005077.s004 (3.10 MB TIF)
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